Manoj K. Patel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Manoj K. Patel has a total of 145 co-authors. Here are the top co-authors by number of shared publications:
Eric R. Wengert
Department of Anesthesiology, University of Virginia Health System, Charlottesville, VA, United States; Neuroscience Graduate Program, University of Virginia School of Medicine, Charlottesville, VA, United States
7 shared publicationsNicholas J. Hargus
Department of Anesthesiology, University of Virginia Health System, Charlottesville, VA 22908, USA; Neuroscience Graduate Program, University of Virginia Health System, Charlottesville, VA 22908, USA
7 shared publicationsEdward H. Bertram
Neuroscience Graduate Program, University of Virginia Health System, Charlottesville, VA 22908, USA; Department of Neurology, University of Virginia Health System, Charlottesville, VA 22908, USA
6 shared publicationsIan C. Wenker
Department of Anesthesiology, University of Virginia Health System
6 shared publicationsPravin K. Wagley
Department of Anesthesiology, University of Virginia, Charlottesville, VA, United States
6 shared publicationsMatteo Ottolini
Department of Anesthesiology, University of Virginia Health System, Charlottesville, VA 22908, USA
5 shared publications
Latest Publications
- Open Access
- 10 August 2026
- Published by SAGE Publications in Epilepsy Currents
Neurocentric No More? Oligodendrocyte Dysfunction Supports Epileptogenesis
Olig2-Specific Loss-of-Function Slc35a2 Results in Hypomyelination and Spontaneous Seizures Bartel TM, Ghosh C, Bisaha K, Khoury J, Nemes-Baran A, Blumcke I, Najm I. Epilepsia 2026; 67: 950-965.
- 10 August 2026
- Published by SAGE Publications in Epilepsy Currents
Open AccessNeurocentric No More? Oligodendrocyte Dysfunction Supports Epileptogenesis
Olig2-Specific Loss-of-Function Slc35a2 Results in Hypomyelination and Spontaneous Seizures Bartel TM, Ghosh C, Bisaha K, Khoury J, Nemes-Baran A, Blumcke I, Najm I. Epilepsia 2026; 67: 950-965.
- 29 May 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 28 (9) , 2123-2135
Microenvironment T-type calcium channels regulate neuronal and glial processes in tumor cells to promote glioblastoma growth
Background: Glioblastoma (GBM) is the most common primary malignant brain tumor. The aim of this study was to elucidate the role of microenvironment and intrinsic T-type calcium channels (Cav3) in regulating GBM. Methods: We grafted syngeneic GBM cells into Cav3.2 knockout (KO) mice to assess the role of microenvironment T-type calcium channels on GBM growth. We grafted syngeneic GBM cells into the hippocampus along the Schaffer collaterals and performed electrophysiology. We used neurons from wild type (WT) and Cav3.2KO mice in co-culture with GBM stem cells (GSCs) to assess the effects of Cav3.2 on neuron/GSC synaptic connections and tumor cell growth. We performed single-cell RNA sequencing (scRNA-seq) of tumors from WT and Cav3.2KO mice to elucidate the regulation of tumors by the microenvironment. Results: Cav3.2KO in the microenvironment led to significant reduction of GBM growth and prolongation of animal survival. Neuronal Cav3.2 promoted GSC growth in co-culture and neuron/GBM functional synaptic connections in vivo. scRNA-seq showed that microenvironment Cav3.2 regulates neuronal and glial biological processes. Microenvironment Cav3.2 downregulated numerous genes associated with regulating the oligodendrocyte precursor-like cell state in GBM tumors. Treatment of GSCs with the Cav3 blocker mibefradil downregulated genes associated with neuronal processes. The Cav3 blocker drug mibefradil synergized with temozolomide (TMZ) and radiation to reduce in vivo tumor growth and prolong animal survival. Conclusions: The data reveal a role for microenvironment Cav3 in promoting GBM progression through regulating neuronal and glial processes. Targeting both intrinsic and microenvironment Cav3 with the inhibitor mibefradil significantly enhanced the anti-GBM effects of TMZ and radiation.
- 29 May 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 28 (9) , 2123-2135
Microenvironment T-type calcium channels regulate neuronal and glial processes in tumor cells to promote glioblastoma growth
Background: Glioblastoma (GBM) is the most common primary malignant brain tumor. The aim of this study was to elucidate the role of microenvironment and intrinsic T-type calcium channels (Cav3) in regulating GBM. Methods: We grafted syngeneic GBM cells into Cav3.2 knockout (KO) mice to assess the role of microenvironment T-type calcium channels on GBM growth. We grafted syngeneic GBM cells into the hippocampus along the Schaffer collaterals and performed electrophysiology. We used neurons from wild type (WT) and Cav3.2KO mice in co-culture with GBM stem cells (GSCs) to assess the effects of Cav3.2 on neuron/GSC synaptic connections and tumor cell growth. We performed single-cell RNA sequencing (scRNA-seq) of tumors from WT and Cav3.2KO mice to elucidate the regulation of tumors by the microenvironment. Results: Cav3.2KO in the microenvironment led to significant reduction of GBM growth and prolongation of animal survival. Neuronal Cav3.2 promoted GSC growth in co-culture and neuron/GBM functional synaptic connections in vivo. scRNA-seq showed that microenvironment Cav3.2 regulates neuronal and glial biological processes. Microenvironment Cav3.2 downregulated numerous genes associated with regulating the oligodendrocyte precursor-like cell state in GBM tumors. Treatment of GSCs with the Cav3 blocker mibefradil downregulated genes associated with neuronal processes. The Cav3 blocker drug mibefradil synergized with temozolomide (TMZ) and radiation to reduce in vivo tumor growth and prolong animal survival. Conclusions: The data reveal a role for microenvironment Cav3 in promoting GBM progression through regulating neuronal and glial processes. Targeting both intrinsic and microenvironment Cav3 with the inhibitor mibefradil significantly enhanced the anti-GBM effects of TMZ and radiation.
- Open Access
- 2 December 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (3)
Base editing rescues seizures and sudden death in a SCN8A mutation-associated developmental epileptic encephalopathy model
SCN8A encodes the voltage-gated sodium channel Na v 1.6, which plays a key role in facilitating neuronal excitability. Mutations in SCN8A , particularly gain-of-function variants, cause SCN8A developmental and epileptic encephalopathy (DEE), a severe epilepsy syndrome characterized by seizures, cognitive dysfunction, movement disorders, and sudden unexpected death in epilepsy (SUDEP). The recurrent SCN8A variant R1872W impairs channel inactivation, causing neuronal hyperexcitability and seizures. Current treatments, including antiseizure medications, are often ineffective for patients with SCN8A DEE, highlighting the need for targeted therapies. We employed base editing to correct the R1872W SCN8A variant. An adenine base editor and guide RNA ( SCN8A -ABE) were packaged within dual PhP.eB-adeno-associated viruses (AAVs) and administered to R1872W mice at P2. SCN8A -ABE significantly increased survival of mice expressing R1872W and either reduced seizure incidence and severity or eliminated seizure occurrence. Electrophysiological recordings revealed a rescue of seizure-associated neuronal hyperexcitability and suppression of the pathogenic persistent sodium current (I NaP ) in treated mice. Comorbidities, including diminished mobility and anxiety-like behaviors, were improved by SCN8A- ABE. These effects were achieved by a 32% absolute reduction in mutant transcripts, accompanied by conversion to SCN8A WT transcripts. Our findings demonstrate base editing as an effective targeted therapeutic approach for SCN8A DEEs by addressing the underlying genetic cause.
- 2 December 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (3)
Open AccessBase editing rescues seizures and sudden death in a SCN8A mutation-associated developmental epileptic encephalopathy model
SCN8A encodes the voltage-gated sodium channel Na v 1.6, which plays a key role in facilitating neuronal excitability. Mutations in SCN8A , particularly gain-of-function variants, cause SCN8A developmental and epileptic encephalopathy (DEE), a severe epilepsy syndrome characterized by seizures, cognitive dysfunction, movement disorders, and sudden unexpected death in epilepsy (SUDEP). The recurrent SCN8A variant R1872W impairs channel inactivation, causing neuronal hyperexcitability and seizures. Current treatments, including antiseizure medications, are often ineffective for patients with SCN8A DEE, highlighting the need for targeted therapies. We employed base editing to correct the R1872W SCN8A variant. An adenine base editor and guide RNA ( SCN8A -ABE) were packaged within dual PhP.eB-adeno-associated viruses (AAVs) and administered to R1872W mice at P2. SCN8A -ABE significantly increased survival of mice expressing R1872W and either reduced seizure incidence and severity or eliminated seizure occurrence. Electrophysiological recordings revealed a rescue of seizure-associated neuronal hyperexcitability and suppression of the pathogenic persistent sodium current (I NaP ) in treated mice. Comorbidities, including diminished mobility and anxiety-like behaviors, were improved by SCN8A- ABE. These effects were achieved by a 32% absolute reduction in mutant transcripts, accompanied by conversion to SCN8A WT transcripts. Our findings demonstrate base editing as an effective targeted therapeutic approach for SCN8A DEEs by addressing the underlying genetic cause.
- Open Access
Base Editing Rescue of Seizures and SUDEP in SCN8A Developmental Epileptic Encephalopathy
SCN8A encodes the sodium channel Na v 1.6; mutations in SCN8A , particularly gain-of-function variants, cause SCN8A developmental and epileptic encephalopathy (DEE), a severe epilepsy syndrome characterized by seizures, cognitive dysfunction, and seizure-induced death. The recurrent SCN8A variant R1872W impairs channel inactivation, causing neuronal hyperexcitability and seizures. Current treatments for SCN8A DEE are often ineffective, highlighting the need for targeted therapies. Here we employed base editing to correct the R1872W SCN8A variant. A modified adenine base editor ( SCN8A -ABE) was packaged within dual PhP.eB-adeno-associated viruses (AAVs) and administered to R1872W mice at P2. SCN8A -ABE significantly increased survival and reduced or eliminated seizures. Neuronal hyperexcitability and heightened sodium currents were attenuated with SCN8A -ABE treatment, and behavioral comorbidities were improved. These effects were achieved by approximately 30% conversion of mutant to wildtype SCN8A transcripts. These findings demonstrate base editing as an effective targeted therapeutic approach for SCN8A DEE by addressing the underlying genetic cause.
Open AccessBase Editing Rescue of Seizures and SUDEP in SCN8A Developmental Epileptic Encephalopathy
SCN8A encodes the sodium channel Na v 1.6; mutations in SCN8A , particularly gain-of-function variants, cause SCN8A developmental and epileptic encephalopathy (DEE), a severe epilepsy syndrome characterized by seizures, cognitive dysfunction, and seizure-induced death. The recurrent SCN8A variant R1872W impairs channel inactivation, causing neuronal hyperexcitability and seizures. Current treatments for SCN8A DEE are often ineffective, highlighting the need for targeted therapies. Here we employed base editing to correct the R1872W SCN8A variant. A modified adenine base editor ( SCN8A -ABE) was packaged within dual PhP.eB-adeno-associated viruses (AAVs) and administered to R1872W mice at P2. SCN8A -ABE significantly increased survival and reduced or eliminated seizures. Neuronal hyperexcitability and heightened sodium currents were attenuated with SCN8A -ABE treatment, and behavioral comorbidities were improved. These effects were achieved by approximately 30% conversion of mutant to wildtype SCN8A transcripts. These findings demonstrate base editing as an effective targeted therapeutic approach for SCN8A DEE by addressing the underlying genetic cause.
- Open Access
- 22 October 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (20)
Parvalbumin interneuron impairment causes synaptic transmission deficits and seizures in SCN8A developmental and epileptic encephalopathy
SCN8A developmental and epileptic encephalopathy (DEE) is a severe epilepsy syndrome resulting from mutations in the voltage-gated sodium channel Na v 1.6, encoded by the gene SCN8A . Na v 1.6 is expressed in excitatory and inhibitory neurons, yet previous studies primarily focus on how SCN8A mutations affect excitatory neurons, with limited studies on the importance of inhibitory interneurons. Parvalbumin (PV) interneurons are a prominent inhibitory interneuron subtype that expresses Na v 1.6. To assess PV interneuron function within SCN8A DEE, we used 2 mouse models harboring patient-derived SCN8A gain-of-function variants, Scn8a D/+ , where the SCN8A variant N1768D is expressed globally, and Scn8a W/+ -PV, where the SCN8A variant R1872W is selectively expressed in PV interneurons. Expression of the R1872W SCN8A variant selectively in PV interneurons led to development of spontaneous seizures and seizure-induced death. Electrophysiology studies showed that Scn8a D/+ and Scn8a W/+ -PV interneurons were susceptible to depolarization block and exhibited increased persistent sodium current. Evaluation of synaptic connections between PV interneurons and pyramidal cells showed synaptic transmission deficits in Scn8a D/+ and Scn8a W/+ -PV interneurons. Together, our findings indicate that PV interneuron failure via depolarization block along with inhibitory synaptic impairment likely elicits an overall inhibitory reduction in SCN8A DEE, leading to unchecked excitation and ultimately resulting in seizures and seizure-induced death.
- 22 October 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (20)
Open AccessParvalbumin interneuron impairment causes synaptic transmission deficits and seizures in SCN8A developmental and epileptic encephalopathy
SCN8A developmental and epileptic encephalopathy (DEE) is a severe epilepsy syndrome resulting from mutations in the voltage-gated sodium channel Na v 1.6, encoded by the gene SCN8A . Na v 1.6 is expressed in excitatory and inhibitory neurons, yet previous studies primarily focus on how SCN8A mutations affect excitatory neurons, with limited studies on the importance of inhibitory interneurons. Parvalbumin (PV) interneurons are a prominent inhibitory interneuron subtype that expresses Na v 1.6. To assess PV interneuron function within SCN8A DEE, we used 2 mouse models harboring patient-derived SCN8A gain-of-function variants, Scn8a D/+ , where the SCN8A variant N1768D is expressed globally, and Scn8a W/+ -PV, where the SCN8A variant R1872W is selectively expressed in PV interneurons. Expression of the R1872W SCN8A variant selectively in PV interneurons led to development of spontaneous seizures and seizure-induced death. Electrophysiology studies showed that Scn8a D/+ and Scn8a W/+ -PV interneurons were susceptible to depolarization block and exhibited increased persistent sodium current. Evaluation of synaptic connections between PV interneurons and pyramidal cells showed synaptic transmission deficits in Scn8a D/+ and Scn8a W/+ -PV interneurons. Together, our findings indicate that PV interneuron failure via depolarization block along with inhibitory synaptic impairment likely elicits an overall inhibitory reduction in SCN8A DEE, leading to unchecked excitation and ultimately resulting in seizures and seizure-induced death.
- Open Access
- 27 December 2023
- Published by SAGE Publications in Epilepsy Currents
- Vol. 24 (1) , 62-64
Unspooling the Thread: VIP Interneurons Linked With Autism Spectrum Disorder Behaviors but Not Seizures in Dravet Syndrome
VIP Interneuron Impairment Promotes In Vivo Circuit Dysfunction and Autism-Related Behaviors in Dravet Syndrome Goff KM, Liebergall SR, Jiang E, Somarowthu A, Goldberg EM. Cell Rep . 2023;42(6):112628. doi: 10.1016/j.celrep.2023.112628 Dravet syndrome (DS) is a severe neurodevelopmental disorder caused by loss-of-function variants in SCN1A, which encodes the voltage-gated sodium channel subunit Nav1.1. We recently showed that neocortical vasoactive intestinal peptide interneurons (VIP-INs) express Nav1.1 and are hypoexcitable in DS (Scn1a +/- ) mice. Here, we investigate VIP-IN function at the circuit and behavioral level by performing in vivo 2-photon calcium imaging in awake wild-type (WT) and Scn1a +/- mice. VIP-IN and pyramidal neuron activation during behavioral transition from quiet wakefulness to active running is diminished in Scn1a +/- mice, and optogenetic activation of VIP-INs restores pyramidal neuron activity to WT levels during locomotion. VIP-IN selective Scn1a deletion reproduces core autism-spectrum-disorder-related behaviors in addition to cellular- and circuit-level deficits in VIP-IN function, but without epilepsy, sudden death, or avoidance behaviors seen in the global model. Hence, VIP-INs are impaired in vivo, which may underlie non-seizure cognitive and behavioral comorbidities in DS.
- 27 December 2023
- Published by SAGE Publications in Epilepsy Currents
- Vol. 24 (1) , 62-64
Open AccessUnspooling the Thread: VIP Interneurons Linked With Autism Spectrum Disorder Behaviors but Not Seizures in Dravet Syndrome
VIP Interneuron Impairment Promotes In Vivo Circuit Dysfunction and Autism-Related Behaviors in Dravet Syndrome Goff KM, Liebergall SR, Jiang E, Somarowthu A, Goldberg EM. Cell Rep . 2023;42(6):112628. doi: 10.1016/j.celrep.2023.112628 Dravet syndrome (DS) is a severe neurodevelopmental disorder caused by loss-of-function variants in SCN1A, which encodes the voltage-gated sodium channel subunit Nav1.1. We recently showed that neocortical vasoactive intestinal peptide interneurons (VIP-INs) express Nav1.1 and are hypoexcitable in DS (Scn1a +/- ) mice. Here, we investigate VIP-IN function at the circuit and behavioral level by performing in vivo 2-photon calcium imaging in awake wild-type (WT) and Scn1a +/- mice. VIP-IN and pyramidal neuron activation during behavioral transition from quiet wakefulness to active running is diminished in Scn1a +/- mice, and optogenetic activation of VIP-INs restores pyramidal neuron activity to WT levels during locomotion. VIP-IN selective Scn1a deletion reproduces core autism-spectrum-disorder-related behaviors in addition to cellular- and circuit-level deficits in VIP-IN function, but without epilepsy, sudden death, or avoidance behaviors seen in the global model. Hence, VIP-INs are impaired in vivo, which may underlie non-seizure cognitive and behavioral comorbidities in DS.
- Open Access
- 31 October 2023
- Published by SAGE Publications in Epilepsy Currents
- Vol. 23 (6) , 369-371
A Water Nymph’s Curse and the Serotonergic Mechanism of Postictal Breathing Dysfunction
Sudden unexpected death in epilepsy (SUDEP) has been linked to respiratory dysfunction, but the mechanisms underlying this association remain unclear. Here we found that both focal and generalized convulsive seizures (GCSs) in epilepsy patients caused a prolonged decrease in the hypercapnic ventilatory response (HCVR; a measure of respiratory CO2 chemoreception). We then studied Scn1a R1407X/+ (Dravet syndrome; DS) and Scn8a N1768D/+ (D/+) mice of both sexes, two models of SUDEP, and found that convulsive seizures caused a postictal decrease in ventilation and severely depressed the HCVR in a subset of animals. Those mice with severe postictal depression of the HCVR also exhibited transient postictal hypothermia. A combination of blunted HCVR and abnormal thermoregulation is known to occur with dysfunction of the serotonin (5-hydroxytryptamine; 5-HT) system in mice. Depleting 5-HT with para-chlorophenylalanine (PCPA) mimicked seizure-induced hypoventilation, partially occluded the postictal decrease in the HCVR, exacerbated hypothermia, and increased postictal mortality in DS mice. Conversely, pretreatment with the 5-HT agonist fenfluramine reduced postictal inhibition of the HCVR and hypothermia. These results are consistent with the previous observation that seizures cause transient impairment of serotonergic neuron function, which would be expected to inhibit the many aspects of respiratory control dependent on 5-HT, including baseline ventilation and the HCVR. These results provide a scientific rationale to investigate the interictal and/or postictal HCVR as noninvasive biomarkers for those at high risk of seizure-induced death, and to prevent SUDEP by enhancing postictal 5-HT tone.
- 31 October 2023
- Published by SAGE Publications in Epilepsy Currents
- Vol. 23 (6) , 369-371
Open AccessA Water Nymph’s Curse and the Serotonergic Mechanism of Postictal Breathing Dysfunction
Sudden unexpected death in epilepsy (SUDEP) has been linked to respiratory dysfunction, but the mechanisms underlying this association remain unclear. Here we found that both focal and generalized convulsive seizures (GCSs) in epilepsy patients caused a prolonged decrease in the hypercapnic ventilatory response (HCVR; a measure of respiratory CO2 chemoreception). We then studied Scn1a R1407X/+ (Dravet syndrome; DS) and Scn8a N1768D/+ (D/+) mice of both sexes, two models of SUDEP, and found that convulsive seizures caused a postictal decrease in ventilation and severely depressed the HCVR in a subset of animals. Those mice with severe postictal depression of the HCVR also exhibited transient postictal hypothermia. A combination of blunted HCVR and abnormal thermoregulation is known to occur with dysfunction of the serotonin (5-hydroxytryptamine; 5-HT) system in mice. Depleting 5-HT with para-chlorophenylalanine (PCPA) mimicked seizure-induced hypoventilation, partially occluded the postictal decrease in the HCVR, exacerbated hypothermia, and increased postictal mortality in DS mice. Conversely, pretreatment with the 5-HT agonist fenfluramine reduced postictal inhibition of the HCVR and hypothermia. These results are consistent with the previous observation that seizures cause transient impairment of serotonergic neuron function, which would be expected to inhibit the many aspects of respiratory control dependent on 5-HT, including baseline ventilation and the HCVR. These results provide a scientific rationale to investigate the interictal and/or postictal HCVR as noninvasive biomarkers for those at high risk of seizure-induced death, and to prevent SUDEP by enhancing postictal 5-HT tone.
- Open Access
- 23 September 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (19) , 14467
EpiPro, a Novel, Synthetic, Activity-Regulated Promoter That Targets Hyperactive Neurons in Epilepsy for Gene Therapy Applications
Epileptogenesis is characterized by intrinsic changes in neuronal firing, resulting in hyperactive neurons and the subsequent generation of seizure activity. These alterations are accompanied by changes in gene transcription networks, first with the activation of early-immediate genes and later with the long-term activation of genes involved in memory. Our objective was to engineer a promoter containing binding sites for activity-dependent transcription factors upregulated in chronic epilepsy (EpiPro) and validate it in multiple rodent models of epilepsy. First, we assessed the activity dependence of EpiPro: initial electrophysiology studies found that EpiPro-driven GFP expression was associated with increased firing rates when compared with unlabeled neurons, and the assessment of EpiPro-driven GFP expression revealed that GFP expression was increased ~150× after status epilepticus. Following this, we compared EpiPro-driven GFP expression in two rodent models of epilepsy, rat lithium/pilocarpine and mouse electrical kindling. In rodents with chronic epilepsy, GFP expression was increased in most neurons, but particularly in dentate granule cells, providing in vivo evidence to support the “breakdown of the dentate gate” hypothesis of limbic epileptogenesis. Finally, we assessed the time course of EpiPro activation and found that it was rapidly induced after seizures, with inactivation following over weeks, confirming EpiPro’s potential utility as a gene therapy driver for epilepsy.
- 23 September 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (19) , 14467
Open AccessEpiPro, a Novel, Synthetic, Activity-Regulated Promoter That Targets Hyperactive Neurons in Epilepsy for Gene Therapy Applications
Epileptogenesis is characterized by intrinsic changes in neuronal firing, resulting in hyperactive neurons and the subsequent generation of seizure activity. These alterations are accompanied by changes in gene transcription networks, first with the activation of early-immediate genes and later with the long-term activation of genes involved in memory. Our objective was to engineer a promoter containing binding sites for activity-dependent transcription factors upregulated in chronic epilepsy (EpiPro) and validate it in multiple rodent models of epilepsy. First, we assessed the activity dependence of EpiPro: initial electrophysiology studies found that EpiPro-driven GFP expression was associated with increased firing rates when compared with unlabeled neurons, and the assessment of EpiPro-driven GFP expression revealed that GFP expression was increased ~150× after status epilepticus. Following this, we compared EpiPro-driven GFP expression in two rodent models of epilepsy, rat lithium/pilocarpine and mouse electrical kindling. In rodents with chronic epilepsy, GFP expression was increased in most neurons, but particularly in dentate granule cells, providing in vivo evidence to support the “breakdown of the dentate gate” hypothesis of limbic epileptogenesis. Finally, we assessed the time course of EpiPro activation and found that it was rapidly induced after seizures, with inactivation following over weeks, confirming EpiPro’s potential utility as a gene therapy driver for epilepsy.
- Open Access
- 27 March 2023
- Published by SAGE Publications in Epilepsy Currents
- Vol. 23 (3) , 185-187
Waiting to Inhale: Preventing Fatality From Seizure-Induced Apnea
- 27 March 2023
- Published by SAGE Publications in Epilepsy Currents
- Vol. 23 (3) , 185-187
Open AccessWaiting to Inhale: Preventing Fatality From Seizure-Induced Apnea
- Open Access
- 22 September 2022
- Published by SAGE Publications in Epilepsy Currents
- Vol. 22 (6) , 395-397
That’s a Wrap: Could Controlling Activity-Regulated Myelination Prevent Absence Seizures?
Maladaptive Myelination Promotes Generalized Epilepsy Progression Knowles JK, Xu H, Soane C, Batra A, Saucedo T, Frost E, Tam LT, Fraga D, Ni L, Villar K, Talmi S, Huguenard JR, Monje M. Nat Neurosci . 2022;25(5):596-606. doi: 10.1038/s41593-022-01052-2 Activity-dependent myelination can fine-tune neural network dynamics. Conversely, aberrant neuronal activity, as occurs in disorders of recurrent seizures (epilepsy), could promote maladaptive myelination, contributing to pathogenesis. In this study, we tested the hypothesis that activity-dependent myelination resulting from absence seizures, which manifest as frequent behavioral arrests with generalized electroencephalography (EEG) spike-wave discharges, promote thalamocortical network hypersynchrony and contribute to epilepsy progression. We found increased oligodendrogenesis and myelination specifically within the seizure network in two models of generalized epilepsy with absence seizures (Wag/Rij rats and Scn8a +/mut mice), evident only after epilepsy onset. Aberrant myelination was prevented by pharmacological seizure inhibition in Wag/Rij rats. Blocking activity-dependent myelination decreased seizure burden over time and reduced ictal synchrony as assessed by EEG coherence. These findings indicate that activity-dependent myelination driven by absence seizures contributes to epilepsy progression; maladaptive myelination may be pathogenic in some forms of epilepsy and other neurological diseases.
- 22 September 2022
- Published by SAGE Publications in Epilepsy Currents
- Vol. 22 (6) , 395-397
Open AccessThat’s a Wrap: Could Controlling Activity-Regulated Myelination Prevent Absence Seizures?
Maladaptive Myelination Promotes Generalized Epilepsy Progression Knowles JK, Xu H, Soane C, Batra A, Saucedo T, Frost E, Tam LT, Fraga D, Ni L, Villar K, Talmi S, Huguenard JR, Monje M. Nat Neurosci . 2022;25(5):596-606. doi: 10.1038/s41593-022-01052-2 Activity-dependent myelination can fine-tune neural network dynamics. Conversely, aberrant neuronal activity, as occurs in disorders of recurrent seizures (epilepsy), could promote maladaptive myelination, contributing to pathogenesis. In this study, we tested the hypothesis that activity-dependent myelination resulting from absence seizures, which manifest as frequent behavioral arrests with generalized electroencephalography (EEG) spike-wave discharges, promote thalamocortical network hypersynchrony and contribute to epilepsy progression. We found increased oligodendrogenesis and myelination specifically within the seizure network in two models of generalized epilepsy with absence seizures (Wag/Rij rats and Scn8a +/mut mice), evident only after epilepsy onset. Aberrant myelination was prevented by pharmacological seizure inhibition in Wag/Rij rats. Blocking activity-dependent myelination decreased seizure burden over time and reduced ictal synchrony as assessed by EEG coherence. These findings indicate that activity-dependent myelination driven by absence seizures contributes to epilepsy progression; maladaptive myelination may be pathogenic in some forms of epilepsy and other neurological diseases.